Subscribe
John Baron explains why he is adding to the portfolios' exposure
John Rosier discards a sizeable Europe holding in favour of an attractively priced UK medical specialist
John Baron explains why the sceptics may be wrong about the sector
The portfolio's performance is up on the first quarter, but it is still lagging the All-Share – time in the market, not timing the market is key
John Baron questions accepted norms and explains the portfolios’ approach
John Rosier, prompted by the Conviviality fiasco, has cut his losers and found some stimulating new investments with a strong bull case behind them
Both momentum and defensive investing have done badly so far this year. This might be just bad luck
John Baron reports on a good first quarter relative to benchmarks, and explains why cash levels are unusually high
It is vital to know how a portfolio is performing. Here are the tools to make that possible
John Rosier explains why he's aiming to build up exposure to companies that are benefiting from advances in technology